PRAXIS PRECISION MEDICINES, INC. Restricted Cash and Cash Equivalents
PRAXIS PRECISION MEDICINES, INC. (PRAX) had Restricted Cash and Cash Equivalents of $416.00 thousand as of 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2025-02-28
- 2024-12-31: Restricted Cash and Cash Equivalents $416.00K.
- 2023-12-31: Restricted Cash and Cash Equivalents $416.00K.
- 2022-12-31: Restricted Cash and Cash Equivalents $416.00K.
- 2021-12-31: Restricted Cash and Cash Equivalents $1.02M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2024-12-31 | $416.00K 10-K · filed 2025-02-28 |
| 2023-12-31 | $416.00K 10-K · filed 2025-02-28 |
| 2022-12-31 | $416.00K 10-K · filed 2024-03-05 |
| 2021-12-31 | $1.02M 10-K · filed 2023-02-07 |
| 2020-12-31 | $600.00K 10-K · filed 2022-02-28 |
| 2019-12-31 | $600.00K 10-K · filed 2021-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |